Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Platelet-rich Plasma Left Side

Phase 1Biologic

WWake Forest University Health Sciences

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Androgenic AlopeciaNot yet recruiting

Androgenic AlopeciaPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Androgenic Alopecia

NCT03474718

Clinical

Trials by Indication[1]

Androgenic Alopecia1 trial

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

Not yet recruiting·WWake Forest University Health Sciences·Phase 1·NCT03474718·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Platelet-rich Plasma Left Side. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Platelet-rich Plasma Left Side compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Platelet-rich Plasma Left Side. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: WWake Forest University Health Sciences

Related News